President Trump’s ambitious plan to revive the American pharmaceutical industry and bring back manufacturing jobs to the United States has been met with both enthusiasm and skepticism. The idea of a domestic manufacturing renaissance, particularly in the realm of generic medicines, sounds promising, but the reality on the ground paints...